The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

The past decade has seen the emergence of immunotherapy as a prime approach to cancer
treatment, revolutionizing the management of many types of cancer. Despite the promise of …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

Next-generation sequencing has revealed that more than 50% of human cancers harbour
mutations in enzymes that are involved in chromatin organization. Tumour cells not only are …

Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with
histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune …

During the course of malignant cancer progression, neoplastic cells undergo dynamic and
reversible transitions between multiple phenotypic states, the extremes of which are defined …

The past decade has highlighted the central role of epigenetic processes in cancer
causation, progression and treatment. Next-generation sequencing is providing a window …

DNA, mRNA and microRNA are released and circulate in the blood of cancer patients.
Changes in the levels of circulating nucleic acids have been associated with tumour burden …

Lung cancer is the leading cause of cancer-related mortality worldwide. Advances in our
understanding of the genomics of lung cancer have led to substantial progress in the …